ARegulation•businesswire•
Agilent’s MMR IHC Panel pharmDx (Dako Omnis) Receives European IVDR Certification as a Companion Diagnostic Test for Colorectal Cancer
Sentiment:Positive (65)
Summary
(NYSE:A) SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab). MMR IHC Panel
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by businesswire